| venlafaxine extended release / Generic mfg. |
NCT00083980: Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD) |
|
|
| Terminated | 2 | 16 | US | Venlafaxine ER, Effexor XR, Sugar pill, No brand name, Kava | National Center for Complementary and Integrative Health (NCCIH) | Anxiety Disorders | 06/04 | 08/04 | | |
NCT00620776: Combined Treatment for Generalized Anxiety Disorder (GAD) |
|
|
| Completed | 2 | 69 | US | Cognitive Behavioral Therapy, Venlafaxine XR, Effexor extended release | University of Pennsylvania, National Institute of Mental Health (NIMH) | Generalized Anxiety Disorder | 03/08 | 03/08 | | |
| Completed | 2 | 396 | Canada, Europe, RoW | GSK372475, venlafaxine, placebo | GlaxoSmithKline | Depressive Disorder | 12/08 | 12/08 | | |
| Terminated | 2 | 35 | Canada | Lu AA34893, Venlafaxine extended release, Placebo | H. Lundbeck A/S | Major Depressive Disorder | 01/09 | 02/09 | | |
NCT00797966: Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder |
|
|
| Completed | 2 | 850 | US | OPC-34712, Generic Name: Brexpiprazole, Placebo, ADT, Each individual will receive one of the following 6 ADTs:, Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine CR (Paxil CR), Sertraline (Zoloft), Desvenlafaxine (Pristiq), Venalfaxine XR (Effexor XR) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder | 06/10 | 07/10 | | |
NCT00854100: Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder |
|
|
| Completed | 2 | 231 | US | Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d) | Forest Laboratories, Gedeon Richter Ltd. | Major Depressive Disorder | 12/10 | 12/10 | | |
NCT03605784: Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder |
|
|
| Completed | 2 | 232 | US | Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d) | Allergan, Gedeon Richter Ltd. | Major Depressive Disorder | 12/10 | 12/10 | | |
NCT01114698: A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder |
|
|
| Terminated | 2 | 12 | US | Venlafaxine XR, Placebo, JNJ26489112 | Janssen Research & Development, LLC | Depression | 01/12 | 02/12 | | |
NCT01447576: Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder |
|
|
| Completed | 2 | 1036 | US | ADT, Anti-depressant Drug Therapy, OPC-34712 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder | 12/12 | 12/12 | | |
NCT00742573: Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics |
|
|
| Completed | 2 | 170 | US | Antidepressants through Texas Medication Algorithm (TMA), Celexa, Lexapro, Paxil, Zoloft, Effexor XR, Wellbutrin, Cymbalta, Pamelor, Remeron, Brief Interpersonal Psychotherapy (IPT-B) | New York State Psychiatric Institute, National Institute of Mental Health (NIMH) | Major Depressive Disorder | 01/14 | 01/14 | | |
ChiCTR-TRC-14005143: A traditional chinese medicine clinical intervention study of depressed Parkinson's disease - based on the Wenyang Jieyu method |
|
|
| Recruiting | 2 | 120 | | Formula granule ;Venlafaxine hydrochloride sustained-release capsules | The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine; Level of the institution：, Beijing Municipal Science and Technology Commission | Depressed Parkinson's disease | | | | |
CAR aGAD Ph 2, NCT04965272: A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone |
|
|
| Withdrawn | 2 | 0 | US | Cariprazine 0.75 mg/day, Vraylar, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo | AbbVie | Generalized Anxiety Disorder | 08/21 | 08/21 | | |
| Completed | 1/2 | 56 | Canada | venlafaxine, Effexor, buprenorphine, Temgesic, Subutex, Suboxone, placebo | Centre for Addiction and Mental Health, Reckitt Benckiser LLC | Major Depressive Disorder, Depression | 01/17 | 05/18 | | |
| Completed | 1/2 | 18 | US | venlafaxine XR, Effexor XR, buprenorphine, Temgesic, Subutex, Suboxone, Placebo | Washington University School of Medicine, Reckitt Benckiser LLC | Major Depressive Disorder, Depression | 04/18 | 04/18 | | |
